Automated CD14+ monocyte collection with the autoMNC program of the COM.TEC cell separator

Strasser, Erwin; Schremmer, Melanie; Hendelmeier, Martin; Weiss, Dominik R.; Ringwald, Juergen; Zimmermann, Robert; Weisbach, Volker; Zingsem, J.; Eckstein, Reinhold

doi:10.1111/j.1537-2995.2007.01471.x

Cited by 8 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Defining the MNC apheresis settings, a central requirement was to achieve comparability of target cell yields by similar processing times of the apheresis procedures. Thereby, those settings for the autoMNC programme of the COM.TEC were applied, which have been evaluated before and assure apheresis products, which comply with the customers′ requirements for an optimum MNC harvest and subsequent cell processing . Hence, apheresis procedures with the COM.TEC were accomplished with an inlet blood flow rate of 50 ml per minute during the separation phase and 15 collection cycles with a cycle volume of 350 ml.…”

Section: Methodsmentioning

confidence: 99%

First comparative evaluation of a new leukapheresis technology in non‐cytokine‐stimulated donors

et al. 2013

View full text Add to dashboard Cite

Leukaphereses with the three devices resulted in almost equal total MNC yields. MNC products of the Spectra Optia and the Amicus could be used in preference for the monocyte enrichment by the Elutra system and the leukapheresis procedures could be also favourably applied in patients with low platelet counts. The COM.TEC is more efficient in monocyte and T-cell collection with the disadvantage of high residual non-target cell content in the products.

show abstract

Section: Methodsmentioning

confidence: 99%

First comparative evaluation of a new leukapheresis technology in non‐cytokine‐stimulated donors

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Regarding the RF values, the values of Punzel et al [10] for WBCs, MNCs, and lymphocytes were nearly twice as high when compared to our values. The same applies to the RF values for CD45+, CD3+ and CD14+ cells presented by Strasser et al 2005 [15] and 2007 [18]. It is likely that all these diverse observations in cell loss and the RF may be due to the different calculation formulas used.…”

Section: Discussionmentioning

confidence: 94%

“…Taking the fluid balance into account, we demonstrated a perfect negative correlation between the cell loss and recruitment for all cell populations - the higher the recruitment the lesser the cell loss of the respective cell population in the CBC. Strasser et al [18] demonstrated likewise an inverse correlation between the WBC or PLT loss and the WBC or PLT recruitment, respectively. But in contrast to our data, the perfect correlation of both variables could not be shown.…”

Section: Discussionmentioning

confidence: 99%

Low-Volume Leukapheresis in Non-Cytokine-Stimulated Donors for the Collection of Mononuclear Cells

Anyanwu

Sitzmann

Hetjens

et al. 2018

Transfus Med Hemother

View full text Add to dashboard Cite

Background: There is an increasing demand for products containing mononuclear cells (MNCs) for cellular immune therapy. Hence, leukapheresis is increasingly performed in healthy volunteer donors. Methods: We evaluated 147 low-volume leukapheresis procedures from 77 healthy non-cytokine-stimulated donors. Complete blood counts (CBCs) of the donors were measured before and directly after the procedures as well as from the MNC products. Follow-up CBCs were collected from donors within 21 days. Results: The product hematocrit within a range from 1.2 to 6.0% did not correlate with the collection efficiency of any cell population or the granulocyte and platelet yield. There was a strong correlation between the CBC values before leukapheresis and the cell yield of lymphocytes and monocytes as well as a perfect negative correlation between cell recruitment and cell loss in all cell populations. Furthermore, we observed a significant decrease in the CBC values in all cell populations directly after leukapheresis, which recovered within a mean of 16.1 days (SD ± 2.1 days) and even showed a significant increase in granulocytes and platelets. Conclusion: Low-volume leukapheresis is feasible for the collection of MNCs in which the product hematocrit is negligible for the collection efficiency, cell yield, or contamination of residual cells under operational settings recommended by the manufacturer. Our data suggests that cell recruitment is regulated by the number of cells removed, which may also be the stimulus to induce granulo- and thrombopoiesis within the first days after leukapheresis.

show abstract

“…For this therapeutical approach, important quantities of monocytes are usually required to get enough DCs for vaccination purposes. The plasma needed for the cell cultures [71] is concurrently collected with the mononuclear cells [79–83].…”

Section: Multicomponent Collection Techniquesmentioning

confidence: 99%

Multicomponent apheresis

Zingsem

2010

ISBT Science Series

Self Cite

View full text Add to dashboard Cite

Introduction: An increasing demand for blood components is opposed by a decreasing donor availability for the collection of the required blood components. Furthermore, current stem cell transplantation regiments require the collection of more than one similar or different component from one donor or patient. One strategy for maintaining the patients' supply with the required blood components can be the concurrent collection of more than one component from one donor by apheresis, thus multicomponent apheresis.Scope of multicomponent combinations: Combinations are possible for nearly every kind of blood components. In one session it is possible -depending on the apheresis device -to collect up to four plasma units alone, one or more plasma units and one or two red blood cell (RBC) units, one or more plasma units and one or more platelet units, one or more plasma units and one or two RBC units and one or more platelet units, one or two RBC units and one or more platelet units, two RBC units alone, one or more platelet units.Also in leucocytapheresis the collection of more than one blood component has become a routine procedure. Performing allogeneic stem cell apheresis can lead to a cell dose for two transplantations or to one unit of PBSCs and concurrently collected and frozen mononuclear cells used for donor lymphocyte infusions therapy. Autologous mononuclear cell products (e.g. PBSCs or monocytes for dendritic cell generation) usually are cryoconserved before use and require additional plasmaproteins for cryoconservation. The latter can be obtained by the concurrent collection of plasma during leucocytapheresis. Thus, the combination of cell and plasma units or of cell units of different dose or for different purpose are further examples for the implementation of multicomponent apheresis in tumor therapy. Conclusions:The understanding of apheresis technologies facilitates the use of multicomponent apheresis in the vast application field for tailoring the kind, quantity, and quality of blood components for patient care.

show abstract

Automated CD14+ monocyte collection with the autoMNC program of the COM.TEC cell separator

Cited by 8 publications

References 15 publications

First comparative evaluation of a new leukapheresis technology in non‐cytokine‐stimulated donors

First comparative evaluation of a new leukapheresis technology in non‐cytokine‐stimulated donors

Low-Volume Leukapheresis in Non-Cytokine-Stimulated Donors for the Collection of Mononuclear Cells

Multicomponent apheresis

Contact Info

Product

Resources

About